Abstract Details
|
Shinsuke Fujioka, MD
PRESENTER |
Dr. Fujioka has received research support from Japan Society for the Promotion of Science. |
| No disclosure on file | |
| Audrey Strongosky | No disclosure on file |
| Pawel Tacik, MD (Mayo Clinic Florida, Department of Neurology) | The institution of Dr. Tacik has received research support from Merz Therapeutics, Ipsen Pharma, Anavex Life Sciences Corp. The institution of Dr. Tacik has received research support from Merz Therapeutics, Ipsen Pharma, AbbVie Germany, Boston Scientific Medical Technology, Medtronic. Dr. Tacik has received personal compensation in the range of $5,000-$9,999 for serving as a speaker with Merz Therapeutics, Ipsen Pharma. |
| Bradley F. Boeve, MD, FÂ鶹´«Ã½Ó³» (Mayo Clinic) | Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care. |
| A J. Stoessl, MD, FÂ鶹´«Ã½Ó³» (UBC) | No disclosure on file |
| Matthew Baker | No disclosure on file |
| Rosa Rademakers, PhD (Mayo Clinic Dept of Neuroscience) | Rosa Rademakers, PhD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mayo Clinic. Rosa Rademakers, PhD has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda Therapeutics. Rosa Rademakers, PhD has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer Fondation. Rosa Rademakers, PhD has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Kisick Family Foundation (FTD grant program). The institution of Rosa Rademakers, PhD has received research support from NIH. The institution of Rosa Rademakers, PhD has received research support from DOD. The institution of Rosa Rademakers, PhD has received research support from Flanders Institute for Biotechnology (VIB). The institution of Rosa Rademakers, PhD has received research support from Flanders Funds for Scientific Research. |
| Dennis W. Dickson, MD (Mayo Clinic) | Dr. Dickson has nothing to disclose. |
| Zbigniew K. Wszolek, MD, FÂ鶹´«Ã½Ó³» (Mayo Clinic- Jacksonville) | Dr. Wszolek has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Polish Neurological Society/Via Medica. Dr. Wszolek has received intellectual property interests from a discovery or technology relating to health care. |
| Jeffrey M. Gelfand, MD, MS, FÂ鶹´«Ã½Ó³» (University of California, San Francisco) | Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to Â鶹´«Ã½Ó³» interests or activities. |